Bayer hits back at Iberogast critics
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Bayer Consumer Health has instigated a pharmacy marketing campaign defending its Iberogast gastrointestinal brand following a series of attacks from a German Member of Parliament (MP).
You may also be interested in...
Bayer Stands By Iberogast As German Court Investigates Manslaughter Case
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.